Home  »  Finance   »  Analyst’s Sets Aprea Therapeutics Inc. (NASD...

Analyst’s Sets Aprea Therapeutics Inc. (NASDAQ:APRE) New Target at $7.25: APRE is Now On A Buy List

Aprea Therapeutics Inc. (NASDAQ:APRE) shares fell to a low of $4.85 before closing at $5.06. Intraday shares traded counted 0.32 million, which was 56.51% higher than its 30-day average trading volume of 734.74K. APRE’s previous close was $5.00 while the outstanding shares total 21.19M. The stock’s Relative Strength Index (RSI) is 65.82, with weekly volatility at 6.36% and ATR at 0.27. The APRE stock’s 52-week price range has touched low of $3.88 and a $41.12 high. The stock traded higher over the last trading session, gaining 1.20% on 06/10/21.

Investors have identified the Biotechnology company Aprea Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $108.79 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Aprea Therapeutics Inc. (APRE) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 80.08 million total, with 11.21 million as their total liabilities.

Having a look at the company’s valuation, the company is expected to record -1.66 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on APRE sounds very interesting.

Is the stock of APRE attractive?

In related news, 10% Owner, Redmile Group, LLC sold 500,000 shares of the company’s stock in a transaction that recorded on Dec 28. The sale was performed at an average price of 5.58, for a total value of 2,791,290. As the sale deal closes, the Former 10% holder, 5AM Ventures IV, L.P. now sold 175,000 shares of the company’s stock, valued at 4,427,500. Also, 10% Owner, KDev Investments AB sold 241,703 shares of the company’s stock in a deal that was recorded on Jul 07. The shares were price at an average price of 34.55 per share, with a total market value of 8,350,839. Following this completion of acquisition, the Director, ROCKLAGE SCOTT M now holds 120,164 shares of the company’s stock, valued at 4,001,461. In the last 6 months, insiders have changed their ownership in shares of company stock by 2.10%.

1 out of 5 analysts covering the stock have rated it a Buy, while 4 have maintained a Hold recommendation on Aprea Therapeutics Inc.. 0 analysts has assigned a Sell rating on the APRE stock. The 12-month mean consensus price target for the company’s shares has been set at $7.25.

Leave a Comment

Your email address will not be published. Required fields are marked *